EMS-CHEMIE (EMSN) Q3 2025 earnings summary

Executive summary

• Net sales for January–September 2025 reached CHF 1,491 million, down 6.2% year-over-year, mainly due to currency effects and a strong Swiss Franc.

• Net operating income remains slightly above the previous year, driven by a focus on high-margin specialties and innovations.

• Business in Asian markets showed particularly strong development, supported by the full acquisition of EFTEC China.

• The company expanded its technical sales and development teams in Asia, America, and Europe, generating profitable new business.

Financial highlights

• Net sales decreased to CHF 1,491 million from CHF 1,589 million year-over-year.

• High Performance Polymers net sales fell 6.5% to CHF 1,344 million; Specialty Chemicals net sales declined 3.6% to CHF 147 million.

• Despite lower sales, profitability and margins improved due to cost discipline and innovation.

Outlook and guidance

• The fourth quarter is expected to remain challenging due to ongoing trade conflicts and economic uncertainty.

• Net sales for the full year 2025 are expected to remain below the previous year, but net operating income (EBIT) is projected to be slightly above the previous year.

• The company will continue its sales offensive with innovative specialties and expects to maintain above-average results due to high equity and no debt.